Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 yearsJin Young Ahn, Jun Yong Choi, You Suk Suh et al.|medRxiv|2021Cited by 5